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Background: SYNTAX is a randomized controlled trial comparing percu-
taneous coronary intervention (PCI) using drug-eluting stents with coronary
artery bypass graft surgery (CABG) in patients (pts) with 3 vessel and/or left
main disease. We will analyze health economic data associated with CABG
and PCI in the subset of France compared with select countries in the EU
(Germany, Italy and UK).
Methods: Costs will be estimated using 1-year resource utilization data
including procedural resource use (stents, guidewires etc.), hospitalizations
major procedures and work days lost. Estimates are based on French patterns
of resource utilization, number of hospital days and break down of those in
intensive care, or ward days. Where data did not allow reliable French esti-
mate, a Bayesian statistical model was applied combining the observed
resource utilization with priors based on data on less rare events. Effects are
measured in terms of MACCE-free survival.
Results: In France, 105 pts were randomized to CABG and 103 to PCI in
the SYNTAX trial. There were 156 hospitalizations in the first year in CABG
pts compared with 139 in PCI pts. Overall, CABG pts in France spent 23.3
days (d) in hospital (see Table). PCI pts spent 9.2 d in hospital. After the index
procedure, pts in the CABG arm spent 9.1 d in hospital whereas PCI pts spent
5.7 d. Economic data comparing short- and long-term medical care costs for
pts with left main and/or 3-vessel CAD treated with either DES or CABG will
be available at time of presentation.
Conclusions: Additional analyses of the procedural resources utilized and
costs associated with the procedures will be presented as a comparison
between the French subset and countries in the EU. 
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The renin-angiotensin-aldosterone system is a major therapeutic target
in coronary artery disease (CAD). Recent data suggest that plasma aldos-
terone has a high prognostic value in acute coronary syndrome (ACS). We
tested whether plasma aldosterone could predict clinical outcome in
patients undergoing scheduled percutaneous coronary revascularization
(PCR). Methods: From June 2001 to September 2002, we included all con-
secutive patients referred to Lille’s University Hospital for scheduled PCR.
Blood samples were taken during the PCR. The primary endpoint was car-
diac death throughout at least 12 months of follow-up. Results: 807
patients were included, with a mean age of 61 years. Most were men
(78%), smokers (71%). 32% were diabetics, mean LVEF was 58±15% and
93% received stents. 50% had stable angina. The mean plasma aldosterone
level was 25(13-45)pg/mL. BMI (p=0.003), NYHA class>1 (p=0.0001)
and elevated baseline troponine (p=0.01) were associated with increased
aldosterone level. Old age (p=0.0001), normal GFR (p=0.01) and betabloc-
kers (p=0.01) were associated with decreased aldosterone level. The mean
follow-up was 14.9 months and there were 40 cardiac deaths during this
period. In multivariate analysis, old age (HR=1.42, p=0.04), low LVEF
(HR=1.58, p=0.001), diabetes mellitus (HR=2.2, p=0.04), a recent history
of ACS (HR=3.23, p=0.02), high usCRP (HR=2.59, p=0.004) and high
plasma aldosterone (HR=3.48, p=0.004) were independent predictors of
cardiac mortality. Conclusion: Plasma aldosterone level seems to have an
independent prognostic value in patients referred for PCR and could be
useful in determining the individual cardiovascular risk. Whether this is
the result of direct deleterious effects (promotion of endothelial dysfunc-
tion, pro-fibrotic, pro-inflammatory and pro-thrombotic effects) or the
marker of a global activation of the neuroendocrine system remains to be
determined. However plasma aldosterone appears to be an attractive risk
marker in CAD.
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Objectives: The use of adjunctive thrombectomy (AT) as device to primary
percutaneous coronary intervention (PCI) for an acute ST segment elevation myo-
cardial infarction (STEMI) has shown clinical benefit in randomized trials.
Whether this benefit could translate to all patients with partial or complete occlu-
sion of a coronary artery in primary PCI remains to be determined.
Methods: From the RICO Survey, all the patients admitted with TIMI
grade 0 or 1 before primary PCI for a STEMI < 12 H after symptom onset
were included in the study. Among the study population, 156 (29%) patients
underwent AT (AT group) and were compared with patients with TIMI grade
0/1 who do not undergo AT (control group, n=384).
 Mean Total Days in Hospital 
Per Patient*
Mean Days in Hospital 
During Follow-up
 CABG PCI CABG PCI
Intensive Care 
Unit (ICU) 8.8 4.3 1.8 1.3
General Ward 10.7 3.7 6.7 4.2
Other Wards 2.5 0.9 0.6 0.2
Total Days 23.3 9.2 9.1 5.7
*Total days in hospital includes days spent during index procedure
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Results: Patients with AT were younger and less frequently hypertensive.
Glycoprotein IIb/IIIa inhibitors were more frequently administrated in the
AT group. However, a decrease in the rate of patients with TIMI 3 flow
grade post PCI was observed in the AT group. Peak creatine kinase was
significantly higher in patients with AT while ischemic time was similar for
the 2 groups. Stenting the infarct-related lesion was less frequent than in the
control group. CV mortality at 30 days and at 1-year were higher in the AT
group (11.4 vs. 5.2 %, p=0.016, and 14.6 vs. 7%, p=0.013) respectively. By
multivariate analysis, AT remains an independent predictor of 1-Y mortality
even when adjusted for potential confounders (HR(95%CI):4.95(2.08-
11.77)). These results were unchanged when the propensity score for AT
was introduced into the model.
Conclusions: In the contemporary era of interventional therapy, this large
observational study revealed that routine use of AT in primary PCI with a
baseline TIMI 0 or 1 flow was not associated with an improved outcome.
Prospective studies are warranted to precisely analyse the impact of AT in
such patients and to further investigate its potential benefit.
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Aim: Compare the effectiveness and safety of drug-eluting stent (DES) vs
bare metal stent (BMS) for percutaneous coronary intervention (PCI) in
patients with chronic renal failure (CRF).
Methods: 1126 patients treated by PCI over one year were divided in
4 patients groups, according to the type of stent used (DES vs BMS) and
the creatinin clearance (CrCl). Clinical and angiographic data were pros-
pectively entered into the web-based "Middle-Care" database. Chronic
renal failure (CRF) was defined by a CrCl < 60 ml/min. The occurrence of
cardiovascular (CV) death, MACCE (Death, myocardial infarction and
stroke) and TLR was recorded at one year follow-up. We report the preli-
minary (6 months) results of patients treated between August 2007 and
January 2008.
Results: 497 patients underwent PCI: 250 (50.3%), 120 (24.1%), 81
(16.3%) and 46 (9.3%) patients were allocated in the BMS, DES, BMS
CRF and DES CRF groups respectively. Mean age was 64 +/- 13 years,
82.5% were male, 24.4% had diabetes, 62.1% had an acute coronary syn-
drom (ACS) and 47% multivessel disease. One year follow-up was com-
pleted for 485 (97.6%) patients: 36 (7.1%) patients died, 54 (10.7%) had
MACCE and 35 (6.9%) underwent TLR. The use of DES was associated
with significantly less CV death and MACCE, a trend for less TLR and the
same stent thrombosis (ST) rate compared with BMS use in patients with
and without CRF (figure).
Conclusions: The use of DES appears to be more effective and at least as
safe as BMS at one year follow up in patients with CRF. Final results will be
available for the meeting. 
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Background: Elderly patients are at higher risk for coronary angioplasty
and few data exist on the safety of drug eluting stent (DES) in this special
population. Objectives: this registry sought to compare bare metal stent (BMS)
and DES short and long term clinical outcome and survival in a cohort of
patients older than 75.
Methods: between September 2007 and august 2008, 2000 patients older
than 75 years old were included in a prospective the multicentric PAPI
registry. Patients were all treated by coronary stenting with either BMS or
DES and were followed for clinical events at the end of the initial hospitalisa-
tion, at 6, 12 and 24 months. Patients were compared according to there DES/
BMS status for the entire cohort and were divided in 3 subgroups according to
there age 75-80, 80-85 and >85 to assess aging influence.
Results: mean age of the total population was 80±3 (75-96). On the overall
population 3318 stents were used for the angioplasty of 3132 lesions. Twenty
seven percent of them were DES. There was a significant decrease of DES use in
older patients (12% patients >85 vs 33% patients <80 p=0.0001). At 6 month
death occured in 3.2% of patients, infarction in 1.5% and stent thrombosis in 1.5%
with no significant difference between type of stent. There was a trend for less
Major Adverse Cardiac events (MACE) in DES patients (6% vs 8%; p=0.07) and
significantly less Major Adverse Cardiac and CerebroVascular events (MACCE)
in DES patients (6% vs 9%; p=0.02). There was less major events for DES than
for BMS patients for the younger group (7%vs13%; p=0.01). In uni or multivariate
analysis stent type was not predictive of adverse event.
Conclusion: PAPI is a multicentric prospective registry aim to evaluate the
outcome of modern coronary angioplasty in patients > 75 years old. DES were
associated with a significant better outcome at 6 month. Thus, at least at 6
month, the use of DES in older patients seems to be safe in older patients.
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